T
Trinity Biotech plc
Biotechnology: In Vitro & In Vivo Diagnostic Substances company
Key Metrics of Trinity Biotech plc
Revenue$102M▲ 0.0% YoYFY 2020
Operating income$82.0K▲ 0.0% YoY
Net profit−$6.0M▲ 0.0% YoY
Shareholders' equity−$2.2M
Market cap$6.3MTRIB · $7.75
Competitors10identified
About Trinity Biotech plc
Sectors
Company details
- Founded
- 1992
- Listed
- Nasdaq: TRIB (since 1992)
Operational Areas of Trinity Biotech plc
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameTrinity Biotech plc
TickerTRIB
ExchangeNasdaq
CountryIreland
SEC CIK0000888721
Listed since1992
IndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
TRIB · Nasdaq · SEC CIK 0000888721
Last price · 23 Oct 2026
$7.75
−0.51%
Market cap$6.3M
P/E—On FY 2020 diluted EPS
Volume10,714
SectorHealth CareBiotechnology: In Vitro & In Vivo Diagnostic Substances
Country · IPOIrelandListed 1992
TRIB share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Trinity Biotech plc
Competitors10identified
Countries2most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | gsk.com | 2022 | United Kingdom | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States | |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.